# John F Dipersio

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 354 papers | 10,929 citations | 45 h-index | 101 g-index |
| 394 ext. papers | 13,856 ext. citations | 5.3 avg, IF | 5.92 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 354 | Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.. *Scientific Reports*, **2022**, 12, 30 | 4.9 | 0 |
| 353 | Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia.. *Blood Cancer Discovery*, **2022**, 3, 32-49 | 7 | 0 |
| 352 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.. *Science Translational Medicine*, **2022**, 14, eabm1375 | 17.5 | 2 |
| 351 | Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.. *Journal of Virology*, **2022**, e0005722 | 6.2 | 4 |
| 350 | PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.. *NAR Cancer*, **2022**, 4, zcac014 | 5.2 | 1 |
| 349 | Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. *Leukemia*, **2021**, | 10.7 | 2 |
| 348 | VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. *Clinical Cancer Research*, **2021**, 27, 1974-1986 | 12.9 | 5 |
| 347 | Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. *Journal of Clinical Investigation*, **2021**, | 15.9 | 3 |
| 346 | A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL). *Blood*, **2021**, 138, 4829-4829 | 2.2 | 0 |
| 345 | Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. *Leukemia and Lymphoma*, **2021**, 1-5 | 1.9 | |
| 344 | Pre-Infusion Neurofilament Light Chain (NfL) Levels Predict the Development of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) - a Multicenter Retrospective Study. *Blood*, **2021**, 138, 2841-2841 | 2.2 | 0 |
| 343 | Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. *Blood*, **2021**, 138, 800-800 | 2.2 | |
| 342 | Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. *Blood*, **2021**, 138, 2550-2550 | 2.2 | 1 |
| 341 | 3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. *Blood*, **2021**, 138, 2690-2690 | 2.2 | |
| 340 | Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model. *Blood*, **2021**, 138, 734-734 | 2.2 | 2 |
| 339 | Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial. *Blood*, **2021**, 138, 3816-3816 | 2.2 | |
| 338 | Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. *Blood*, **2021**, 138, 2849-2849 | 2.2 | |

| | | | |
|---|---|---|---|
| 337 | Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. *Blood*, **2021**, 138, 2691-2691 | 2.2 | |
| 336 | Cedar Trial in Progress: A First in Human, Phase 1/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD. *Blood*, **2021**, 138, 1864-1864 | 2.2 | 1 |
| 335 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. *Blood*, **2021**, | 2.2 | 2 |
| 334 | Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. *Blood*, **2021**, 138, 3904-3904 | 2.2 | |
| 333 | Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. *Blood*, **2021**, 138, 475-475 | 2.2 | 1 |
| 332 | Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. *New England Journal of Medicine*, **2021**, 384, 924-935 | 59.2 | 42 |
| 331 | Co-evolution of tumor and immune cells during progression of multiple myeloma. *Nature Communications*, **2021**, 12, 2559 | 17.4 | 11 |
| 330 | 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. *Leukemia and Lymphoma*, **2021**, 62, 2457-2465 | 1.9 | 2 |
| 329 | BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. *Cancer*, **2021**, 127, 1246-1259 | 6.4 | 6 |
| 328 | Development of [Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1302-1311 | 8.8 | 4 |
| 327 | Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?. *Leukemia and Lymphoma*, **2021**, 62, 749-751 | 1.9 | 1 |
| 326 | Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*, **2021**, 137, 751-762 | 22 | 77 |
| 325 | A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. *Leukemia and Lymphoma*, **2021**, 62, 1441-1449 | 1.9 | 0 |
| 324 | Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. *Leukemia*, **2021**, 35, 2346-2357 | 12.7 | 12 |
| 323 | Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. *Journal of Clinical Oncology*, **2021**, 39, 386-396 | 2.2 | 6 |
| 322 | Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. *Leukemia*, **2021**, | 10.7 | 3 |
| 321 | Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. *Nature Communications*, **2021**, 12, 5086 | 17.4 | 6 |
| 320 | Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. *Oncotarget*, **2021**, 12, 1878-1885 | 5.5 | 1 |

| | | | |
|---|---|---|---|
| 319 | A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. *Scientific Reports*, **2021**, 11, 19343 | 4.9 | 0 |
| 318 | In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [F]FDG and [Cu]Cu-LLP2A PET. *EJNMMI Research*, **2021**, 11, 97 | 3.6 | 0 |
| 317 | Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. *Leukemia Research*, **2021**, 110, 106713 | 2.7 | 2 |
| 316 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. *JCO Precision Oncology*, **2021**, 5, | 3.6 | 2 |
| 315 | Highlights in chronic graft-vs-host disease from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. *Clinical Advances in Hematology and Oncology*, **2021**, 19 Suppl 8, 20-23 | 0.6 | |
| 314 | The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study. *Transplant International*, **2020**, 33, 1089-1098 | 3 | |
| 313 | Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. *Haematologica*, **2020**, 105, e404-e407 | 6.6 | 6 |
| 312 | Insights into the role of the JAK/STAT signaling pathway in graft--host disease. *Therapeutic Advances in Hematology*, **2020**, 11, 2040620720914489 | 5.7 | 6 |
| 311 | Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. *Science Translational Medicine*, **2020**, 12, | 17.5 | 50 |
| 310 | Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. *Blood Advances*, **2020**, 4, 2387-2391 | 7.8 | 5 |
| 309 | Selective targeting of 41 integrin attenuates murine graft versus host disease. *Leukemia*, **2020**, 34, 3100-3104 | 10.7 | 4 |
| 308 | CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. *Blood*, **2020**, 136, 2308-2318 | 2.2 | 55 |
| 307 | Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. *Science Translational Medicine*, **2020**, 12, | 17.5 | 24 |
| 306 | Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. *Blood*, **2020**, 136, 4-5 | 2.2 | |
| 305 | Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML. *Blood*, **2020**, 136, 2-3 | 2.2 | |
| 304 | Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123CD3 Bispecific Dart Molecule, in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 26-28 | 2.2 | 1 |
| 303 | TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 3-4 | 2.2 | |
| 302 | Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT). *Blood*, **2020**, 136, 6-7 | 2.2 | |

| | | | |
|---|---|---|---|
| 301 | Addressing Relapsed Disease Following Hematopoietic Stem Cell Transplantation. *Blood*, **2020**, 136, SCI1-SCI1 | 2.2 | |
| 300 | Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo. *Blood*, **2020**, 136, 22-23 | 2.2 | |
| 299 | Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. *Blood*, **2020**, 136, 3-4 | 2.2 | 1 |
| 298 | Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. *Blood*, **2020**, 136, 43-44 | 2.2 | 10 |
| 297 | Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. *Blood*, **2020**, 136, 16-18 | 2.2 | 7 |
| 296 | Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. *Blood*, **2020**, 136, 19-21 | 2.2 | 2 |
| 295 | The Dual PI3K□Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo. *Blood*, **2020**, 136, 1-2 | 2.2 | 4 |
| 294 | Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. *Blood*, **2020**, 136, 46-48 | 2.2 | 2 |
| 293 | Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant. *Blood*, **2020**, 136, 31-32 | 2.2 | 2 |
| 292 | The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 123-131 | 4.7 | 4 |
| 291 | TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. *Blood Advances*, **2020**, 4, 5011-5024 | 7.8 | 41 |
| 290 | Targeting CXCR4 in AML and ALL. *Frontiers in Oncology*, **2020**, 10, 1672 | 5.3 | 18 |
| 289 | Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. *Nature Communications*, **2020**, 11, 6037 | 17.4 | 21 |
| 288 | A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2223-2228 | 4.7 | 1 |
| 287 | Immunotherapy for T-Cell ALL and T-Cell NHL. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20 Suppl 1, S56-S58 | 2 | 1 |
| 286 | Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. *Cancer Discovery*, **2020**, 10, 1854-1871 | 24.4 | 30 |
| 285 | Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. *Frontiers in Oncology*, **2020**, 10, 608916 | 5.3 | 7 |
| 284 | The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. *American Journal of Transplantation*, **2020**, 20, 589-592 | 8.7 | 12 |

| | | | |
|---|---|---|---|
| 283 | Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2305-2321 | 4.7 | 68 |
| 282 | A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e588-e593 | 2 | 2 |
| 281 | Dynamic host immune response in virus-associated cancers. *Communications Biology*, **2019**, 2, 109 | 6.7 | 20 |
| 280 | Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. *Haematologica*, **2019**, 104, e373-e375 | 6.6 | 8 |
| 279 | Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. *Haematologica*, **2019**, 104, e170-e173 | 6.6 | 2 |
| 278 | A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. *Clinical Cancer Research*, **2019**, 25, 7004-7013 | 12.9 | 13 |
| 277 | Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. *Journal of Clinical Investigation*, **2019**, 129, 2745-2759 | 15.9 | 20 |
| 276 | Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 CD3 Bispecific Dart Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2019**, 134, 460-460 | 2.2 | 2 |
| 275 | Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 733-733 | 2.2 | 11 |
| 274 | Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib. *Blood*, **2019**, 134, 2325-2325 | 2.2 | 1 |
| 273 | Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity. *Blood*, **2019**, 134, 2068-2068 | 2.2 | 1 |
| 272 | Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart Molecule for T-Cell Redirected Therapy. *Blood*, **2019**, 134, 5144-5144 | 2.2 | 3 |
| 271 | Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor. *Blood*, **2019**, 134, 1961-1961 | 2.2 | 2 |
| 270 | Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide. *Blood*, **2019**, 134, 4496-4496 | 2.2 | 2 |
| 269 | Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma. *Blood*, **2019**, 134, 5531-5531 | 2.2 | 1 |
| 268 | Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. *Blood*, **2019**, 134, 3915-3915 | 2.2 | 4 |
| 267 | Mobilized peripheral blood: an updated perspective. *F1000Research*, **2019**, 8, | 3.6 | 17 |
| 266 | Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. *Blood*, **2019**, 134, 364-364 | 2.2 | |

| | | | |
|---|---|---|---|
| 265 | CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease. *Blood*, **2019**, 134, 3200-3200 | 2.2 | |
| 264 | Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair. *Blood*, **2019**, 134, 4420-4420 | 2.2 | |
| 263 | GENESIS: Phase III trial evaluating BL-8040´+´G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. *Future Oncology*, **2019**, 15, 3555-3563 | 3.6 | 12 |
| 262 | ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 625-638 | 4.7 | 874 |
| 261 | Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e76-e85 | 4.7 | 53 |
| 260 | First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood*, **2018**, 131, 2515-2527 | 2.2 | 194 |
| 259 | An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. *Leukemia*, **2018**, 32, 1970-1983 | 10.7 | 173 |
| 258 | Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14 | 56.2 | 342 |
| 257 | Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. *Leukemia*, **2018**, 32, 2483-2494 | 10.7 | 41 |
| 256 | Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. *Bone Marrow Transplantation*, **2018**, 53, 826-831 | 4.4 | 55 |
| 255 | Acute graft-versus-host disease following lung transplantation in a patient with a novel mutation. *Thorax*, **2018**, 73, 489-492 | 7.3 | 5 |
| 254 | Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. *Nature Communications*, **2018**, 9, 455 | 17.4 | 99 |
| 253 | Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. *Nature Communications*, **2018**, 9, 275 | 17.4 | 44 |
| 252 | Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1187-1195 | 4.7 | 24 |
| 251 | Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance. *Bone Marrow Transplantation*, **2018**, 53, 949-959 | 4.4 | 2 |
| 250 | OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2018**, 93, 186-189 | 4.6 | 18 |
| 249 | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1125-1134 | 4.7 | 43 |
| 248 | Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice. *Blood*, **2018**, 131, 2594-2596 | 2.2 | 4 |

| | | | |
|---|---|---|---|
| 247 | A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1581-1589 | 4.7 | 38 |
| 246 | Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. *Haematologica*, **2018**, 103, e270-e273 | 6.6 | 1 |
| 245 | Preclinical Development of CD38-Targeted [Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. *Journal of Nuclear Medicine*, **2018**, 59, 216-222 | 8.9 | 37 |
| 244 | Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. *Leukemia Research*, **2018**, 72, 86-91 | 2.7 | 3 |
| 243 | Integrative omics analyses broaden treatment targets in human cancer. *Genome Medicine*, **2018**, 10, 60 | 14.4 | 13 |
| 242 | Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2216-2223 | 4.7 | 9 |
| 241 | Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-tolerance. *Immunity*, **2018**, 48, 923-936.e4 | 32.3 | 28 |
| 240 | Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. *Molecular Cancer Therapeutics*, **2018**, 17, 1739-1751 | 6.1 | 49 |
| 239 | A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. *Blood Cancer Journal*, **2018**, 8, 35 | 7 | 25 |
| 238 | Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 1455-1455 | 2.2 | 12 |
| 237 | Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 CD3 Bispecific Dart Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2018**, 132, 444-444 | 2.2 | 9 |
| 236 | Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2205-2205 | 2.2 | 6 |
| 235 | Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers. *Blood*, **2018**, 132, 2035-2035 | 2.2 | |
| 234 | A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing. *Blood*, **2018**, 132, 2199-2199 | 2.2 | 1 |
| 233 | Characterization of Germline Variants in Multiple Myeloma. *Blood*, **2018**, 132, 4499-4499 | 2.2 | |
| 232 | Modeling S ary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy. *Blood*, **2018**, 132, 340-340 | 2.2 | 1 |
| 231 | Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. *Blood*, **2018**, 132, 118-118 | 2.2 | |
| 230 | Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort. *Blood*, **2018**, 132, 1898-1898 | 2.2 | |

| | | | |
|---|---|---|---|
| 229 | Diabetes mellitus as a poor mobilizer condition. *Blood Reviews*, **2018**, 32, 184-191 | 11.1 | 12 |
| 228 | Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. *PLoS ONE*, **2018**, 13, e0207609 | 3.7 | 1 |
| 227 | Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *New England Journal of Medicine*, **2018**, 379, 2330-2341 | 59.2 | 165 |
| 226 | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. *Blood Cancer Journal*, **2018**, 8, 88 | 7 | 11 |
| 225 | Mutation Clearance after Transplantation for Myelodysplastic Syndrome. *New England Journal of Medicine*, **2018**, 379, 1028-1041 | 59.2 | 64 |
| 224 | Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2047-2055 | 4.7 | 11 |
| 223 | The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. *Leukemia and Lymphoma*, **2017**, 58, 241-243 | 1.9 | |
| 222 | Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia. *Clinical Cancer Research*, **2017**, 23, 3385-3395 | 12.9 | 31 |
| 221 | T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 648-653 | 4.7 | 28 |
| 220 | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *Journal of Hematology and Oncology*, **2017**, 10, 55 | 22.4 | 208 |
| 219 | CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. *Cell*, **2017**, 168, 801-816.e13 | 56.2 | 131 |
| 218 | Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. *Cancer*, **2017**, 123, 1800-1809 | 6.4 | 11 |
| 217 | Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. *Cancer*, **2017**, 123, 3061-3072 | 6.4 | 52 |
| 216 | Risk for Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period. *Transplantation Direct*, **2017**, 3, e145 | 2.3 | 14 |
| 215 | Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1282-1289 | 4.7 | 4 |
| 214 | Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state. *American Journal of Hematology*, **2017**, 92, E549-E552 | 7.1 | |
| 213 | Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. *Journal of Immunology*, **2017**, 198, 3746-3754 | 5.3 | 23 |
| 212 | Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. *Blood*, **2017**, 129, 2680-2692 | 2.2 | 48 |

| | | | |
|---|---|---|---|
| 211 | Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1072-1077 | 4.7 | 20 |
| 210 | Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. *Cancer Medicine*, **2017**, 6, 2814-2821 | 4.8 | 11 |
| 209 | Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2199-2204 | 4.7 | 6 |
| 208 | Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2065-2069 | 4.7 | 16 |
| 207 | Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1736-1743 | 4.7 | 26 |
| 206 | Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. *Transplant Infectious Disease*, **2017**, 19, e12629 | 2.7 | 55 |
| 205 | Tissue polymerase chain reaction for the diagnosis of cytomegalovirus disease after allogeneic hematopoietic cell transplantation. *American Journal of Hematology*, **2017**, 92, E19-E20 | 7.1 | 1 |
| 204 | Acute lymphoblastic leukemia presenting with hypereosinophilia: Case report and review of the literature. *Blood Cells, Molecules, and Diseases*, **2017**, 65, 97-100 | 2.1 | 5 |
| 203 | Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. *Blood*, **2017**, 130, 816-816 | 2.2 | 6 |
| 202 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *New England Journal of Medicine*, **2016**, 375, 2023-2036 | 59.2 | 493 |
| 201 | Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2155-2158 | 4.7 | 6 |
| 200 | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. *Experimental Hematology*, **2016**, 44, 603-13 | 3.1 | 33 |
| 199 | Quality of Life: A Tiebreaker in CEBPA Double-Mutated Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1535-1536 | 4.7 | 1 |
| 198 | Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1851-1860 | 4.7 | 91 |
| 197 | A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2016**, 57, 728-30 | 1.9 | 9 |
| 196 | Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1133-1137 | 4.7 | 19 |
| 195 | Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. *Therapeutic Advances in Hematology*, **2016**, 7, 40-51 | 5.7 | 42 |
| 194 | Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 651-657 | 4.7 | 64 |

| | | | |
|---|---|---|---|
| 193 | A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. *Leukemia and Lymphoma*, **2016**, 57, 453-455 | 1.9 | |
| 192 | Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling. *Blood*, **2016**, 128, 2648-2648 | 2.2 | 1 |
| 191 | The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2745-2745 | 2.2 | 3 |
| 190 | A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). *Blood*, **2016**, 128, 390-390 | 2.2 | 15 |
| 189 | Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2016**, 128, 4599-4599 | 2.2 | 2 |
| 188 | A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). *Blood*, **2016**, 128, 505-505 | 2.2 | 9 |
| 187 | Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. *Journal of Clinical Oncology*, **2016**, 34, 7012-7012 | 2.2 | 1 |
| 186 | Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning. *Blood*, **2016**, 128, 3477-3477 | 2.2 | |
| 185 | Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. *Blood*, **2016**, 128, 4658-4658 | 2.2 | |
| 184 | Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. *Blood*, **2016**, 128, 4698-4698 | 2.2 | |
| 183 | Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. *Blood*, **2016**, 128, 1528-1528 | 2.2 | |
| 182 | DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression. *Blood*, **2016**, 128, 1050-1050 | 2.2 | 1 |
| 181 | Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. *Transfusion*, **2016**, 56, 2331-5 | 2.9 | 6 |
| 180 | Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by 41/7 inhibition. *Blood*, **2016**, 128, 2457-2461 | 2.2 | 20 |
| 179 | Divergent viral presentation among human tumors and adjacent normal tissues. *Scientific Reports*, **2016**, 6, 28294 | 4.9 | 44 |
| 178 | The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1977-9 | 1.9 | 2 |
| 177 | Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1324-1329 | 4.7 | 22 |
| 176 | Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1696-1701 | 4.7 | 44 |

| | | | |
|---|---|---|---|
| 175 | The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1552-1564 | 4.7 | 48 |
| 174 | Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. *Journal of Nuclear Medicine*, **2016**, 57, 640-5 | 8.9 | 26 |
| 173 | A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. *Leukemia and Lymphoma*, **2016**, 57, 2535-40 | 1.9 | 9 |
| 172 | Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1137-1141 | 4.7 | 9 |
| 171 | Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis. *ACS Nano*, **2016**, 10, 5959-70 | 16.7 | 56 |
| 170 | Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. *Blood Reviews*, **2016**, 30, 389-99 | 11.1 | 6 |
| 169 | Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. *Blood*, **2016**, 127, 893-7 | 2.2 | 80 |
| 168 | Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. *Blood*, **2016**, 128, 763-73 | 2.2 | 37 |
| 167 | Marrow Microenvironment and Biology of Mobilization of Stem Cells **2016**, 50-67 | | |
| 166 | Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT **2016**, 452-462 | | 1 |
| 165 | Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. *Leukemia Research*, **2016**, 49, 1-6 | 2.7 | 26 |
| 164 | Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1425-30 | 4.7 | 9 |
| 163 | Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 443-9 | 2 | 28 |
| 162 | Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. *Diabetes*, **2015**, 64, 2969-77 | 0.9 | 43 |
| 161 | Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. *Leukemia Research*, **2015**, 39, 1437-42 | 2.7 | 10 |
| 160 | Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1761-9 | 4.7 | 103 |
| 159 | Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. *JAMA - Journal of the American Medical Association*, **2015**, 314, 811-22 | 27.4 | 242 |
| 158 | Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1153-4 | 4.7 | 12 |

| | | | |
|---|---|---|---|
| 157 | Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature*, **2015**, 518, 552-555 | 50.4 | 503 |
| 156 | Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. *Blood*, **2015**, 126, 2484-90 | 2.2 | 150 |
| 155 | NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 1337-46 | 7.3 | 14 |
| 154 | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica*, **2015**, 100, 479-88 | 6.6 | 174 |
| 153 | [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. *Molecular Therapy*, **2015**, 23, 1110-1122 | 11.7 | 15 |
| 152 | Patterns and functional implications of rare germline variants across 12 cancer types. *Nature Communications*, **2015**, 6, 10086 | 17.4 | 170 |
| 151 | A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. *Blood*, **2015**, 126, 1686-1686 | 2.2 | 1 |
| 150 | Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD). *Blood*, **2015**, 126, 1938-1938 | 2.2 | 7 |
| 149 | The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2546-2546 | 2.2 | 12 |
| 148 | CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. *Blood*, **2015**, 126, 3098-3098 | 2.2 | 1 |
| 147 | Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. *Blood*, **2015**, 126, 610-610 | 2.2 | 1 |
| 146 | GPR18 Controls Reconstitution of Mouse Small Intestine Intraepithelial Lymphocytes following Bone Marrow Transplantation. *PLoS ONE*, **2015**, 10, e0133854 | 3.7 | 15 |
| 145 | A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants. *Blood*, **2015**, 126, 4207-4207 | 2.2 | |
| 144 | Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2015**, 126, 3144-3144 | 2.2 | |
| 143 | Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Blood*, **2015**, 126, 3196-3196 | 2.2 | |
| 142 | Advances in stem cell mobilization. *Blood Reviews*, **2014**, 28, 31-40 | 11.1 | 98 |
| 141 | Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 46-52 | 4.7 | 72 |
| 140 | Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nature Medicine*, **2014**, 20, 1472-8 | 50.5 | 1125 |

| | | | |
|---|---|---|---|
| 139 | Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. *Cancer Cell*, **2014**, 25, 530-42 | 24.3 | 33 |
| 138 | Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. *Blood*, **2014**, 124, 3887-95 | 2.2 | 18 |
| 137 | Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis. *Blood*, **2014**, 124, 2752-4 | 2.2 | 20 |
| 136 | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. *PLoS ONE*, **2014**, 9, e109799 | 3.7 | 89 |
| 135 | SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. *PLoS Computational Biology*, **2014**, 10, e1003665 | 5 | 301 |
| 134 | Suicide genes: monitoring cells in patients with a safety switch. *Frontiers in Pharmacology*, **2014**, 5, 241 | 5.6 | 8 |
| 133 | Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. *PLoS Genetics*, **2014**, 10, e1004462 | 6 | 94 |
| 132 | Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer Cell*, **2014**, 25, 379-92 | 24.3 | 273 |
| 131 | Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study. *Blood*, **2014**, 124, 2535-2535 | 2.2 | 4 |
| 130 | Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2014**, 124, 2557-2557 | 2.2 | 1 |
| 129 | Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135 | 2.2 | 35 |
| 128 | A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. *Blood*, **2014**, 124, 1931-1931 | 2.2 | |
| 127 | Dual-Function Anti-CD47mAbs Induce Tumor Cell Death and Promote Phagocytosis Resulting in Enhanced in Vivo Efficacy. *Blood*, **2014**, 124, 991-991 | 2.2 | |
| 126 | Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. *Blood*, **2014**, 124, 2456-2456 | 2.2 | 1 |
| 125 | Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo. *Blood*, **2014**, 124, 3828-3828 | 2.2 | |
| 124 | Impact of Remission Status on Outcomes in AML Patients ≥60 Years of Age after Allogeneic Stem Cell Transplantation. *Blood*, **2014**, 124, 1263-1263 | 2.2 | |
| 123 | Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. *Blood*, **2014**, 124, 3944-3944 | 2.2 | |
| 122 | A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 5292-5292 | 2.2 | |

| | | | |
|---|---|---|---|
| 121 | Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML. *Blood*, **2014**, 124, 5296-5296 | 2.2 | |
| 120 | Targeting VLA-4 to Reduce GvHD. *Blood*, **2014**, 124, 3829-3829 | 2.2 | 1 |
| 119 | Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. *Blood*, **2014**, 124, 850-850 | 2.2 | |
| 118 | Defining The Mechanism Involved In The Inhibition Of GvHD By Azacytidine In Vivo Through The Use Of FoxP3 Diphtheria Toxin Receptor (Foxp3DTR) Donor T Cells. *Blood*, **2013**, 122, 134-134 | 2.2 | 1 |
| 117 | Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). *Blood*, **2013**, 122, 1496-1496 | 2.2 | 4 |
| 116 | Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. *Blood*, **2013**, 122, 1498-1498 | 2.2 | 8 |
| 115 | Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. *Blood*, **2013**, 122, 2738-2738 | 2.2 | 2 |
| 114 | Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs ). *Blood*, **2013**, 122, 360-360 | 2.2 | 13 |
| 113 | A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. *Blood*, **2013**, 122, 5492-5492 | 2.2 | 3 |
| 112 | Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. *Blood*, **2013**, 122, 650-650 | 2.2 | 7 |
| 111 | A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. *Blood*, **2013**, 122, 3931-3931 | 2.2 | |
| 110 | Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. *Blood*, **2013**, 122, 2816-2816 | 2.2 | |
| 109 | Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 1398-1398 | 2.2 | |
| 108 | IFNR signaling mediates alloreactive T-cell trafficking and GVHD. *Blood*, **2012**, 120, 4093-103 | 2.2 | 97 |
| 107 | New hope for mobilization failures . . . again. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 159-60 | 2.2 | 3 |
| 106 | A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 163-163 | 2.2 | 23 |
| 105 | Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. *Blood*, **2012**, 120, 3763-3763 | 2.2 | 4 |
| 104 | Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. *Blood*, **2012**, 120, 800-800 | 2.2 | 8 |

| | | | |
|---|---|---|---|
| 103 | PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.. *Journal of Clinical Oncology*, **2012**, 30, 6503-6503 | 2.2 | 4 |
| 102 | Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.. *Journal of Clinical Oncology*, **2012**, 30, 6624-6624 | 2.2 | 2 |
| 101 | Genome-Wide Copy Number Analyses Correlated with Outcomes in Untreated Multiple Myeloma Patients. *Blood*, **2012**, 120, 3991-3991 | 2.2 | |
| 100 | Use of FoxP3 Diptheria Toxin Receptor (Foxp3DTR) Donor T Cells to Define the Mechanism Involved in the Inhibition of GvHD by Azacytidine in Vivo. *Blood*, **2012**, 120, 4113-4113 | 2.2 | |
| 99 | Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 943-55 | 4.7 | 28 |
| 98 | Diabetic stem-cell "mobilopathy". *New England Journal of Medicine*, **2011**, 365, 2536-8 | 59.2 | 67 |
| 97 | Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. *Blood*, **2011**, 118, 109-109 | 2.2 | 10 |
| 96 | Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. *Blood*, **2011**, 118, 278-278 | 2.2 | 8 |
| 95 | Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,. *Blood*, **2011**, 118, 3842-3842 | 2.2 | 2 |
| 94 | Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. *Blood*, **2011**, 118, 404-404 | 2.2 | 1 |
| 93 | Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). *Blood*, **2011**, 118, 5146-5146 | 2.2 | 1 |
| 92 | Donor Dual TCR T Cells Preferentially Expand and Mediate Pathologic Alloreactivity in Acute Graft Versus Host Disease. *Blood*, **2011**, 118, 1972-1972 | 2.2 | |
| 91 | Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. *Blood*, **2011**, 118, 494-494 | 2.2 | |
| 90 | A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. *Blood*, **2011**, 118, 3616-3616 | 2.2 | |
| 89 | Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. *Blood*, **2011**, 118, 809-809 | 2.2 | |
| 88 | Effect of a Novel Nucleoside Analogue, Triciribine Phosphate (TCN-P) on Murine Acute Graft-Vrs-Host Disease (aGvHD). *Blood*, **2011**, 118, 2977-2977 | 2.2 | |
| 87 | Phase I Study of Cladribine (2-chlorodeoxyadenosie), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. *Blood*, **2011**, 118, 3609-3609 | 2.2 | |
| 86 | High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. *Blood*, **2011**, 118, 1830-1830 | 2.2 | |

| | | | |
|---|---|---|---|
| 85 | Can every patient be mobilized?. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 519-23 | 4.2 | 7 |
| 84 | Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. *Blood*, **2010**, 116, 1060-1060 | 2.2 | 2 |
| 83 | Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. *Blood*, **2010**, 116, 1063-1063 | 2.2 | 0 |
| 82 | Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML). *Blood*, **2010**, 116, 2190-2190 | 2.2 | 8 |
| 81 | Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. *Blood*, **2010**, 116, 823-823 | 2.2 | 1 |
| 80 | Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome. *Blood*, **2010**, 116, 608-608 | 2.2 | |
| 79 | Detection of Novel Mutations In MDS/AML by Whole Genome Sequencing. *Blood*, **2010**, 116, 299-299 | 2.2 | |
| 78 | A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation.. *Blood*, **2010**, 116, 4512-4512 | 2.2 | |
| 77 | Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, **2009**, 27, 4767-73 | 2.2 | 533 |
| 76 | Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. *Oncology Reviews*, **2009**, 3, 59-70 | 4.3 | |
| 75 | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood*, **2009**, 113, 5720-6 | 2.2 | 597 |
| 74 | Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*□ ) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.. *Blood*, 2009, 114, 3218-3218 | 2.2 | 1 |
| 73 | Mobilization with Plerixafor (Mozobil □ )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.. *Blood*, **2009**, 114, 3224-3224 | 2.2 | 3 |
| 72 | Plerixafor (Mozobi □ )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (. *Blood*, **2009**, 114, 3230-3230 | 2.2 | 2 |
| 71 | Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/□Blood, **2009**, 114, 33-33 | 2.2 | 2 |
| 70 | Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD).. *Blood*, **2009**, 114, 3326-3326 | 2.2 | 1 |
| 69 | Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. *Blood*, **2009**, 114, 3417-3417 | 2.2 | 1 |
| 68 | A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. *Blood*, **2009**, 114, 3693-3693 | 2.2 | 9 |

| | | | |
|---|---|---|---|
| 67 | Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study.. *Blood*, **2009**, 114, 528-528 | 2.2 | 1 |
| 66 | Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.. *Blood*, **2009**, 114, 633-633 | 2.2 | 11 |
| 65 | A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. *Blood*, **2009**, 114, 787-787 | 2.2 | 4 |
| 64 | A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. *Blood*, **2009**, 114, 842-842 | 2.2 | 4 |
| 63 | Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis.. *Blood*, **2009**, 114, 872-872 | 2.2 | 2 |
| 62 | MCL1 Haploinsufficiency Protects Mice From MYC-Induced Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 764-764 | 2.2 | |
| 61 | Epigenetic Control of GvHD and Gvl Using the Hypomethylating Agent Azacitidine.. *Blood*, **2009**, 114, 2447-2447 | 2.2 | |
| 60 | Comparable Disease-Free and Overall Survival After Well-Matched Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research.. *Blood*, **2009**, 114, 526-526 | 2.2 | |
| 59 | Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 1045-1056 | 4.7 | 267 |
| 58 | Reply to Jaber et al.. *Infection Control and Hospital Epidemiology*, **2008**, 29, 189-190 | 2 | 1 |
| 57 | Months Report from the Phase 3 Study of Plerixafor+G-CSF VS. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with NHL.. *Blood*, **2008**, 112, 1136-1136 | 2.2 | 3 |
| 56 | Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. *Blood*, **2008**, 112, 1944-1944 | 2.2 | 8 |
| 55 | Similar 5-Year Survival after Peripheral Blood Autotransplants (AutoPB) Versus HLA Matched Sibling Myeloablative Transplants (AlloBMT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. *Blood*, **2008**, 112, 2168-2168 | 2.2 | 2 |
| 54 | Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma.. *Blood*, **2008**, 112, 2175-2175 | 2.2 | 1 |
| 53 | A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. *Blood*, **2008**, 112, 2595-2595 | 2.2 | 6 |
| 52 | 12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma. *Blood*, **2008**, 112, 3312-3312 | 2.2 | 2 |
| 51 | Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Blood*, **2008**, 112, 346-346 | 2.2 | 12 |
| 50 | Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor. *Blood*, **2008**, 112, 3476-3476 | 2.2 | 7 |

| | | | |
|---|---|---|---|
| 49 | Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML). *Blood*, **2008**, 112, 560-560 | 2.2 | 6 |
| 48 | Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF. *Blood*, **2008**, 112, 615-615 | 2.2 | 5 |
| 47 | A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/Ml or >5,000 Copies/Ml X 2. *Blood*, **2008**, 112, 4340-4340 | 2.2 | |
| 46 | Generation of Treg-Like Cells from CD4+CD25- T Cells Occurs Via Both Foxp3 Dependent and Independent Pathways. *Blood*, **2008**, 112, 813-813 | 2.2 | |
| 45 | Azacitidine-Induced Changes in the MDS Methylome Are Associated with Clinical Responses. *Blood*, **2008**, 112, 2691-2691 | 2.2 | |
| 44 | Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. *Blood*, **2008**, 112, 4427-4427 | 2.2 | |
| 43 | FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. *Blood*, **2007**, 110, 1855-1855 | 2.2 | 1 |
| 42 | Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells with Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice.. *Blood*, **2007**, 110, 2219-2219 | 2.2 | 1 |
| 41 | Generation of Treg-Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.. *Blood*, **2007**, 110, 62-62 | 2.2 | 0 |
| 40 | Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.. *Blood*, **2007**, 110, 867-867 | 2.2 | 3 |
| 39 | A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. *Blood*, **2007**, 110, 1451-1451 | 2.2 | |
| 38 | M2-10B4 Mesenchymal Stromal Cells Confer an In Vitro Protective Effect of Murine mCGPR/+ Acute Promyelocytic Leukemic Cells Against Chemotherapy.. *Blood*, **2007**, 110, 2844-2844 | 2.2 | |
| 37 | Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.. *Blood*, **2007**, 110, 1203-1203 | 2.2 | |
| 36 | Phase II Study of Low-Dose Decitabine for the Front-Line Treatment of Older Patients with Acute Myeloid Leukemia (AML).. *Blood*, **2006**, 108, 1984-1984 | 2.2 | 9 |
| 35 | Phenotypic and Functional Analysis of T-Cells Mobilized in HLA-Matched Sibling Donors Following Treatment with the Chemokine Antagonist AMD3100.. *Blood*, **2006**, 108, 3001-3001 | 2.2 | 1 |
| 34 | A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin Disease, and PK Is Similar to That of Non-Cancer Patients.. *Blood*, **2006**, 108, 3053-3053 | 2.2 | 3 |
| 33 | Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success.. *Blood*, **2006**, 108, 3380-3380 | 2.2 | 1 |
| 32 | Salvage Therapy with Flag/Idarubicin/Mylotarg (Flag-IM) Results in a Superior CR/CRp Rate and Low Toxicity When Compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in Patients with Relapsed and Refractory AML.. *Blood*, **2006**, 108, 4576-4576 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 31 | HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.. *Blood*, **2006**, 108, 53-53 | 2.2 | 6 |
| 30 | CXCR4/SDF-1 Is a Key Regulator for Leukemia Migration and Homing to the BM: Impact of AMD3100 on In Vivo Response to Chemotherapy.. *Blood*, **2006**, 108, 569-569 | 2.2 | 1 |
| 29 | Impact of Disease and Mobilizing Agents on Initial and Remobilization Failure.. *Blood*, **2006**, 108, 5222-5222 | 2.2 | |
| 28 | Forced Expression of the [illegible]Mutant Inosine Monophosphate Dehydrogenase II Results in Physiologically Significant Resistance to Mycophenolic Acid In Vitro.. *Blood*, **2006**, 108, 5480-5480 | 2.2 | |
| 27 | Prolonged Engraftment and/or Primary Graft Failure Following Allogenic Stem Cell Transplant in Patients Treated with Dasatinib.. *Blood*, **2006**, 108, 5259-5259 | 2.2 | |
| 26 | In Vivo Bioluminescence Imaging (BLI) and Sequential 18F]FHBG microPET Imaging Studies of Human T Cell (huT) Trafficking, Expansion and Xenogeneic Graft-Versus-Host-Disease (XGVHD) Following Different Routes of T Cell Administration.. *Blood*, **2006**, 108, 5178-5178 | 2.2 | |
| 25 | Allogeneic Recipients of Ex-Vivo Manipulated Donor T Cells Have Altered Plasma Analyte Profiles Compared to Recipients of Unmanipulated T Cells.. *Blood*, **2006**, 108, 3227-3227 | 2.2 | |
| 24 | A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).. *Blood*, **2005**, 106, 1854-1854 | 2.2 | 4 |
| 23 | Human CD34+Cells Mobilized by AMD3100 Demonstrate Enhanced NOD/SCID Repopulating Function Compared to CD34+ Cells Mobilized by Granulocyte Colony Stimulating Factor.. *Blood*, **2005**, 106, 1962-1962 | 2.2 | 3 |
| 22 | AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin[illegible] Disease (HD).. *Blood*, **2005**, 106, 1979-1979 | 2.2 | 3 |
| 21 | AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.. *Blood*, **2005**, 106, 246-246 | 2.2 | 4 |
| 20 | Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).. *Blood*, **2005**, 106, 3237-3237 | 2.2 | 5 |
| 19 | Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.. *Blood*, **2005**, 106, 3458-3458 | 2.2 | |
| 18 | Inosine Monophosphate Dehydrogenase II Mutant (Thr-333-Ile + Ser-351-Tyr) Does Not Confer Resistance to Mycophenolic Acid In Vivo.. *Blood*, **2005**, 106, 5226-5226 | 2.2 | |
| 17 | Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID [illegible]2M Null Mice: A New Xenogeneic Model for GvHD.. *Blood*, **2005**, 106, 3106-3106 | 2.2 | |
| 16 | Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.. *Blood*, **2005**, 106, 5257-5257 | 2.2 | |
| 15 | Kinetics of Hematopoietic Progenitor Cell Mobilization with Cyclophosphamide or Cyclophosphamide Plus AMD3100 Using a Mouse Model.. *Blood*, **2005**, 106, 5217-5217 | 2.2 | |
| 14 | Large Scale Ex Vivo GMP Expanded, Activated Human T Cells Consistently Induce Lethal GvHD in a Mouse Xenotransplant Model - A New Way To Study Treatments for Acute GvHD.. *Blood*, **2005**, 106, 5242-5242 | 2.2 | |

| | | | |
|---|---|---|---|
| 13 | Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.. *Blood*, **2005**, 106, 5224-5224 | 2.2 | |
| 12 | A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.. *Blood*, **2005**, 106, 1800-1800 | 2.2 | |
| 11 | Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.. *Blood*, **2004**, 104, 1823-1823 | 2.2 | 3 |
| 10 | A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies.. *Blood*, **2004**, 104, 3341-3341 | 2.2 | 4 |
| 9 | A Murine Xenograft Model for Human T Cell Mediated Graft Versus Host Disease.. *Blood*, **2004**, 104, 4977-4977 | 2.2 | |
| 8 | GMP Scale up for a Clinical Gene Therapy Trial - High Efficiency Human T Cell Expansion and Transduction in a Closed Culture System Utilizing Serumfree Medium and Low IL-2 Concentrations.. *Blood*, **2004**, 104, 5250-5250 | 2.2 | |
| 7 | Reduced Intensity Allografts for Acute Myeloid Leukemia: Defining the Role of Conditioning and Donor Alloreactivity.. *Blood*, **2004**, 104, 5191-5191 | 2.2 | |
| 6 | In Vivo Suicide Gene Therapy of Human T Lymphocytes To Prevent Graft Versus Host Disease in a Murine Xenograft Model.. *Blood*, **2004**, 104, 4979-4979 | 2.2 | |
| 5 | Once Daily Ganciclovir (ODG) as Initial Pre-Emptive Therapy (PT) Delayed until Threshold Viral Load ≥10,000 Copies/ml: A Safe and Effective Strategy for Post-Allogeneic Stem Cell Transplant (ASCT) Patients.. *Blood*, **2004**, 104, 3158-3158 | 2.2 | |
| 4 | Stem cells stat, please!. *Blood*, **2003**, 102, 2711-2711 | 2.2 | |
| 3 | Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. *Blood*, **2001**, 98, 266-71 | 2.2 | 203 |
| 2 | Thrombopoietin therapy increases platelet yields in healthy platelet donors. *Blood*, **2001**, 98, 1339-45 | 2.2 | 81 |
| 1 | Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604 | | 3 |